SG Americas Securities’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $23.9M | Buy |
141,613
+82,346
| +139% | +$12.2M | 0.01% | 548 |
|
|
2026
Q1 | $7.81M | Sell |
59,267
-75,263
| -56% | -$9.99M | 0.01% | 879 |
|
|
2025
Q4 | $19.1M | Buy |
134,530
+119,339
| +786% | +$17.3M | 0.02% | 518 |
|
|
2025
Q3 | $2.13M | Buy |
15,191
+10,357
| +214% | +$1.4M | 0.01% | 915 |
|
|
2025
Q2 | $608K | Sell |
4,834
-170,779
| -97% | -$19.6M | ﹤0.01% | 1520 |
|
|
2025
Q1 | $19.4M | Buy |
175,613
+174,551
| +16,436% | +$22.1M | 0.06% | 201 |
|
|
2024
Q4 | $145K | Sell |
1,062
-7,022
| -87% | -$869K | ﹤0.01% | 2439 |
|
|
2024
Q3 | $931K | Sell |
8,084
-34,394
| -81% | -$4.72M | ﹤0.01% | 1137 |
|
|
2024
Q2 | $5.85M | Buy |
+42,478
| New | +$5.83M | 0.03% | 486 |
|
|
2024
Q1 | – | Sell |
-7,180
| Closed | -$946K | – | 3269 |
|
|
2023
Q4 | $946K | Sell |
7,180
-17,273
| -71% | -$1.99M | 0.01% | 1056 |
|
|
2023
Q3 | $2.75M | Buy |
+24,453
| New | +$2.57M | 0.03% | 558 |
|
|
2023
Q2 | – | Sell |
-30,030
| Closed | -$3.04M | – | 2861 |
|
|
2023
Q1 | $3.04M | Buy |
30,030
+22,676
| +308% | +$2.36M | 0.04% | 464 |
|
|
2022
Q4 | $878K | Buy |
+7,354
| New | +$861K | 0.01% | 1070 |
|
|
2022
Q3 | – | Sell |
-20,700
| Closed | -$2.02M | – | 3427 |
|
|
2022
Q2 | $2.02M | Sell |
20,700
-22,553
| -52% | -$2.08M | 0.02% | 744 |
|
|
2022
Q1 | $4.05M | Sell |
43,253
-76
| -0.2% | -$6.44K | 0.03% | 514 |
|
|
2021
Q4 | $3.69M | Buy |
43,329
+5,131
| +13% | +$472K | 0.02% | 645 |
|
|
2021
Q3 | $3.66M | Buy |
38,198
+3,223
| +9% | +$304K | 0.02% | 752 |
|
|
2021
Q2 | $3.4M | Sell |
34,975
-19,636
| -36% | -$1.88M | 0.02% | 795 |
|
|
2021
Q1 | $5.31M | Buy |
54,611
+48,039
| +731% | +$5.04M | 0.03% | 491 |
|
|
2020
Q4 | $630K | Sell |
6,572
-9,356
| -59% | -$904K | ﹤0.01% | 1818 |
|
|
2020
Q3 | $1.53M | Buy |
15,928
+4,576
| +40% | +$529K | 0.01% | 929 |
|
|
2020
Q2 | $1.39M | Sell |
11,352
-6,814
| -38% | -$753K | 0.01% | 1106 |
|
|
2020
Q1 | $1.57M | Buy |
18,166
+16,821
| +1,251% | +$1.65M | 0.01% | 949 |
|
|
2019
Q4 | $145K | Sell |
1,345
-2,234
| -62% | -$234K | ﹤0.01% | 2716 |
|
|
2019
Q3 | $323K | Sell |
3,579
-1,413
| -28% | -$132K | ﹤0.01% | 2117 |
|
|
2019
Q2 | $421K | Buy |
4,992
+2,886
| +137% | +$237K | ﹤0.01% | 1989 |
|
|
2019
Q1 | $186K | Buy |
2,106
+135
| +7% | +$11.3K | ﹤0.01% | 2623 |
|
|
2018
Q4 | $141K | Buy |
1,971
+157
| +9% | +$15K | ﹤0.01% | 2549 |
|
|
2018
Q3 | $223K | Sell |
1,814
-27,426
| -94% | -$3.11M | ﹤0.01% | 2507 |
|
|
2018
Q2 | $2.87M | Buy |
29,240
+27,904
| +2,089% | +$2.5M | 0.03% | 711 |
|
|
2018
Q1 | $111K | Sell |
1,336
-3,092
| -70% | -$261K | ﹤0.01% | 2878 |
|
|
2017
Q4 | $344K | Buy |
+4,428
| New | +$302K | ﹤0.01% | 2085 |
|
|
2017
Q3 | – | Sell |
-2,326
| Closed | -$107K | – | 3656 |
|
|
2017
Q2 | $107K | Sell |
2,326
-36,446
| -94% | -$1.77M | ﹤0.01% | 2869 |
|
|
2017
Q1 | $1.68M | Sell |
38,772
-20,897
| -35% | -$895K | 0.01% | 1004 |
|
|
2016
Q4 | $2.31M | Buy |
59,669
+56,428
| +1,741% | +$2.55M | 0.02% | 836 |
|
|
2016
Q3 | $164K | Buy |
+3,241
| New | +$161K | ﹤0.01% | 2654 |
|
|
2016
Q2 | – | Sell |
-7,091
| Closed | -$280K | – | 2868 |
|
|
2016
Q1 | $280K | Buy |
+7,091
| New | +$281K | ﹤0.01% | 2024 |
|
|
2015
Q4 | – | Sell |
-16,353
| Closed | -$651K | – | 2886 |
|
|
2015
Q3 | $651K | Buy |
16,353
+12,202
| +294% | +$590K | ﹤0.01% | 984 |
|
|
2015
Q2 | $198K | Sell |
4,151
-10,072
| -71% | -$427K | ﹤0.01% | 1994 |
|
|
2015
Q1 | $565K | Sell |
14,223
-1,510
| -10% | -$54K | ﹤0.01% | 1399 |
|
|
2014
Q4 | $351K | Buy |
+15,733
| New | +$298K | ﹤0.01% | 1922 |
|
|
2013
Q4 | – | Sell |
-13,310
| Closed | -$151K | – | 2878 |
|
|
2013
Q3 | $151K | Buy |
13,310
+4,508
| +51% | +$62K | ﹤0.01% | 2378 |
|
|
2013
Q2 | $118K | Buy |
+8,802
| New | +$108K | ﹤0.01% | 2015 |
|
Other funds holding NBIX
SG Americas Securities's NBIX Position: Q2 2026 in Review
SG Americas Securities increased its Neurocrine Biosciences (NBIX) stake by 139% in Q2 2026, buying an estimated $12.2M and bringing the position to 141,613 shares worth $23.9M. The position accounts for 0.01% of the portfolio, ranked #548.
SG Americas Securities first reported a position in NBIX in Q2 2013 and has held it in 43 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- SG Americas Securities held 141,613 shares of Neurocrine Biosciences worth $23.9M as of Q2 2026.
- SG Americas Securities bought 82,346 Neurocrine Biosciences shares in Q2 2026, an estimated $12.2M.
- Neurocrine Biosciences made up 0.01% of SG Americas Securities's portfolio in Q2 2026, its #548 holding.
- SG Americas Securities first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 43 quarters since.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.